MedTrace Logo

The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis

NCT03080740 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2017-03-15

No results posted yet for this study

Summary

Randomized, double blind, positive drug parallel comparison, multi-centre clinical trial to assess the Efficacy and Safety of Clindamycin palmitate hydrochloride dispersible tablet for the treatment of bacterial vaginosis

Conditions

  • Bacterial Vaginosis

Interventions

DRUG

Clindamycin palmitate hydrochloride dispersible tablet

300mg, oral after meal, twice daily, a total of 7days

DRUG

Metronidazole Tablet

400mg, oral after meal , twice daily, a total of 7days

Sponsors & Collaborators

  • Guangzhou Yipinhong Pharmaceutical CO.,LTD

    lead INDUSTRY

Principal Investigators

  • Zhaohui Liu, MD · Peking University First Hospital

  • Shangrong Fan, MD · Peking University Shenzhen Hospital

  • Long Sui, MD · Affiliated Gynecology and Obstetrics Hospital of Fudan University

  • Ruifang An, MD · First Affiliated Hospital of Xi 'an Jiaotong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-07-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03080740 on ClinicalTrials.gov